ES2139633T3 - Derivados de oxazolidina con propiedades anti-diabetica y anti-obesidad, su preparacion y su utilizacion terapeutica. - Google Patents

Derivados de oxazolidina con propiedades anti-diabetica y anti-obesidad, su preparacion y su utilizacion terapeutica.

Info

Publication number
ES2139633T3
ES2139633T3 ES93306812T ES93306812T ES2139633T3 ES 2139633 T3 ES2139633 T3 ES 2139633T3 ES 93306812 T ES93306812 T ES 93306812T ES 93306812 T ES93306812 T ES 93306812T ES 2139633 T3 ES2139633 T3 ES 2139633T3
Authority
ES
Spain
Prior art keywords
oxazolidine
diabetic
derivatives
preparation
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93306812T
Other languages
English (en)
Inventor
Takashi Fujita
Takao Yoshioka
Shinji Yoshioka
Toshihiko Fujiwara
Hiroyoshi Horikoshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of ES2139633T3 publication Critical patent/ES2139633T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPUESTOS DE LA FORMULA (I): EN DONDE: R ES UN GRUPO ALKILO; X ES OXIGENO O AZUFRE; Y ES UN ATOMO DE HIDROGENO O -A-COOH, EN QUE A ES UN GRUPO ALKILENO, AR ES ARILO O UN GRUPO ARILO SUSTITUIDO; Y LAS SALES Y ESTERES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, QUE SE PUEDEN UTILIZAR PARA EL TRATAMIENTO O PROFILAXIS DE LA DIABETES, LA OBESIDAD, LA HIPERLIPEMIA, LA HIPERGLICEMIA, COMPLICACIONES DE HIPERTENSION Y OSTEOPOROSIS RELACIONADAS CON LA OBESIDAD Y LA DIABETES.
ES93306812T 1992-08-31 1993-08-27 Derivados de oxazolidina con propiedades anti-diabetica y anti-obesidad, su preparacion y su utilizacion terapeutica. Expired - Lifetime ES2139633T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23114092 1992-08-31

Publications (1)

Publication Number Publication Date
ES2139633T3 true ES2139633T3 (es) 2000-02-16

Family

ID=16918916

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93306812T Expired - Lifetime ES2139633T3 (es) 1992-08-31 1993-08-27 Derivados de oxazolidina con propiedades anti-diabetica y anti-obesidad, su preparacion y su utilizacion terapeutica.

Country Status (22)

Country Link
US (1) US5436257A (es)
EP (1) EP0590793B1 (es)
JP (1) JP3201891B2 (es)
KR (1) KR940003955A (es)
CN (1) CN1036588C (es)
AT (1) ATE185564T1 (es)
AU (1) AU663611B2 (es)
CA (1) CA2105149A1 (es)
CZ (1) CZ287027B6 (es)
DE (1) DE69326736T2 (es)
DK (1) DK0590793T3 (es)
ES (1) ES2139633T3 (es)
FI (1) FI933802A (es)
GR (1) GR3031887T3 (es)
HK (1) HK1011979A1 (es)
HU (1) HUT67087A (es)
IL (1) IL106839A (es)
NO (1) NO302121B1 (es)
NZ (1) NZ248532A (es)
RU (1) RU2090564C1 (es)
TW (1) TW318181B (es)
ZA (1) ZA936324B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498621A (en) * 1992-05-01 1996-03-12 Pfizer Inc. Oxazolidinedione hypoglycemic agents
TW363959B (en) * 1994-03-23 1999-07-11 Sankyo Co Thiazolidine and oxazolidine derivatives, their preparation and their medical use
IL113313A (en) * 1994-04-11 1999-09-22 Sankyo Co Heterocyclic compounds and pharmaceutical compositions containing the same
SK111195A3 (en) * 1994-09-13 1997-06-04 Sandoz Technology Ltd Bicyclic ethers substituted with oxazole and thiazole, process for producing thereof and pharmaceutical composition containing same
JPH09136877A (ja) * 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
EP0783888A1 (en) 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
TW399051B (en) * 1996-01-31 2000-07-21 Ssp Co Ltd A novel benzoazine thiazolidinedione derivative and pharmaceutical composition for reducing blood glucose
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
KR100579765B1 (ko) 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
AU2995497A (en) * 1996-07-26 1997-11-19 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
WO2006041921A2 (en) * 2004-10-05 2006-04-20 Auspex Pharmaceuticals, Inc. Preparation and uses of rhodanine derivatives
JP5732453B2 (ja) * 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN115433144B (zh) * 2022-10-09 2023-09-19 燃点(南京)生物医药科技有限公司 一种脂肪酸酯类化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
JPS6242903A (ja) 1985-08-16 1987-02-24 Earth Chem Corp Ltd ハエ誘引剤
WO1988009661A1 (en) * 1987-06-10 1988-12-15 Pfizer Inc. Oxazolidin-2-one derivatives as hypoglycemic agents
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
JPH0231079A (ja) 1988-07-20 1990-02-01 Kubota Ltd 作業車の変速操作構造
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
US5143930A (en) 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
GB9023583D0 (en) 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
CZ287027B6 (en) 2000-08-16
AU4496593A (en) 1994-03-10
KR940003955A (ko) 1994-03-14
NO933080D0 (no) 1993-08-30
CA2105149A1 (en) 1994-03-01
US5436257A (en) 1995-07-25
CN1090281A (zh) 1994-08-03
EP0590793A1 (en) 1994-04-06
DE69326736T2 (de) 2000-06-08
FI933802A0 (fi) 1993-08-31
HK1011979A1 (en) 1999-07-23
EP0590793B1 (en) 1999-10-13
JPH06157522A (ja) 1994-06-03
ZA936324B (en) 1994-03-22
GR3031887T3 (en) 2000-02-29
CZ176393A3 (en) 1994-04-13
RU2090564C1 (ru) 1997-09-20
HUT67087A (en) 1995-01-30
TW318181B (es) 1997-10-21
NO933080L (no) 1994-03-01
HU9302449D0 (en) 1993-11-29
DK0590793T3 (da) 2000-01-31
ATE185564T1 (de) 1999-10-15
NO302121B1 (no) 1998-01-26
IL106839A0 (en) 1993-12-08
AU663611B2 (en) 1995-10-12
CN1036588C (zh) 1997-12-03
FI933802A (fi) 1994-03-01
IL106839A (en) 1998-02-22
NZ248532A (en) 1995-04-27
DE69326736D1 (de) 1999-11-18
JP3201891B2 (ja) 2001-08-27

Similar Documents

Publication Publication Date Title
ES2139633T3 (es) Derivados de oxazolidina con propiedades anti-diabetica y anti-obesidad, su preparacion y su utilizacion terapeutica.
NO940610L (no) Oksazolidinedionderivater, deres fremstilling og anvendelse
RU93048539A (ru) Производные оксазолидина, обладающие противодиабетическими свойствами и действием против ожирения, их получение и терапевтическое применение
TW290543B (es)
NO962239L (no) Benzimidazolderivater, deres fremstilling og terapeutiske anvendelse
NO173867C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzamider
DK0458551T3 (da) Spiro-isoquinolin-pyrrolidiner og analoge deraf, som er anvendelige som aldosereduktase-inhibitorer.
DK0467621T3 (da) Anvendelse af N-phenyl-N-alkylsulfonylurinstoffertil fremstilling af lægemidler mod cancer
AU641686B2 (en) Benzanilides
ES8606295A1 (es) Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas.
AU558153B2 (en) Pyrimidine derivatives of 1,3-thiazole
DK0534655T3 (da) Thiazolidin-2,4-dioner til behandling af hypertension

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 590793

Country of ref document: ES